<DOC>
	<DOCNO>NCT00003493</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy consist liposomal doxorubicin , vincristine , dexamethasone treat patient newly diagnose previously treat multiple myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess response rate duration response multiple myeloma treat doxorubicin HCl liposome , vincristine , dexamethasone . II . Define qualitative quantitative toxic effect regimen patient . OUTLINE : Patients stratify newly diagnose ( group A ) previously treat ( group B ) patient . Patients receive doxorubicin HCl liposome IV 2.5 hour , follow vincristine bolus IV 5 minute day 1 . Dexamethasone administer orally IV day 1-4 . Treatment repeat every 4 week minimum 6 course , 2 course maximum response unless unacceptable toxic effect disease progression occur . Patients follow death . PROJECTED ACCRUAL : A maximum 33 patient group A 34 patient group B accrue study within 6-14 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove newly diagnose previously treat multiple myeloma At least one chemotherapy regimen four regimen Pancytopenia relate multiple myeloma allow At least 50 % plasma cell bone marrow Splenomegaly OR Plasma cell leukemia No solitary bone solitary extramedullary plasmacytoma PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 2,500/mm3 OR neutrophil count least 1,000/mm3 ( previously treat patient platelet count least 75,000/mm3 must neutrophil count great 500/mm3 ) Platelet count least 75,000/mm3 ( previously treat patient must platelet count least 45,000/mm3 ) Thrombocytopenia related idiopathic thrombocytopenic purpura B12 folate deficiency allow Hepatic : Bilirubin great upper limit normal ( ULN ) ALT AST great 2 time ULN ( unless great 1/3 liver involved tumor , case ALT AST must great 5 time ULN ) Renal : Not specify Cardiovascular : LVEF least 50 % MUGA scan echocardiogram No New York Heart Association class II great cardiac disease Other : Not pregnant nursing Fertile patient must use effective contraception No prior malignancy within 5 year , except : Adequately treat basal squamous cell skin cancer Adequately treat carcinoma situ cervix No uncontrollable physical , mental , emotional disorder No history hypersensitivity doxorubicin HCL liposomal PEGylated formulation drug No active infection require IV antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Patients previously fail treatment doxorubicin HCl liposome , vincristine , dexamethasone ( VAD ) allow anthracycline therapy least 6 month , prior anthracycline exposure great 300 mg/m2 No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Concurrent radiotherapy control pain prevent fracture allow Surgery : Prior surgery allow recover</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2001</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>